



Health Technology Assessment (HTA) of New vaccines and New Target Groups and Impact Evaluation and Effectiveness of Current Vaccination Strategies

Guest Editors:

Prof. Dr. Paolo Bonanni

Department of Health Sciences,
University of Florence, 50134
Florence, Italy

Dr. Angela Bechini

Department of Health Sciences,
University of Florence, 50134
Florence, Italy

Dr. Sara Boccalini

Department of Health Sciences,
University of Florence, 50134
Florence, Italy

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear colleagues,

In the current global health scenario, there is a strong need for evidence-based choices to rationalize the use of limited available resources and maximize results in terms of health, especially for prevention activities.

The aim of the Special issue is to collect HTA studies on vaccination that can provide careful and indepth analysis of both epidemiological/clinical data and organization vaccination practices, also including the economic evaluations of new vaccines (such as RSV and SARS-CoV-2) or new vaccination strategies. We hope research articles on the impact of vaccination programs analyzing the reduction of notifications, hospitalizations, or deaths due to vaccine-preventable diseases (measles, rubella, varicella, et al.) would be appreciated. Monitoring studies of vaccination coverage trends over time and seroepidemiological studies are also welcome.

The final objective is to give voice to all vaccination practices that, at an acceptable and sustainable cost, can improve the quality of life of all people.

Prof. Dr. Angela Bechini

Prof. Paolo Bonanni

Prof. Sara Boccalini





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com